Trials / Completed
CompletedNCT00210457
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanreotide (Autogel formulation) |
Timeline
- Start date
- 2000-09-01
- Primary completion
- 2002-07-15
- Completion
- 2002-07-15
- First posted
- 2005-09-21
- Last updated
- 2020-03-31
Locations
17 sites across 2 countries: France, Switzerland
Source: ClinicalTrials.gov record NCT00210457. Inclusion in this directory is not an endorsement.